Advaxis Applies for Approximately $5.0 Million in Grants in Response to U.S. Department of Defense Solicitation

NORTH BRUNSWICK, N.J. -- May 4 2009 -- Advaxis, Inc. (OTCBB: ADXS) has responded to solicitations from the US Department of Defense (DoD) requesting development projects for live Listeria vaccines. The company has applied for approximately $5.0 million in grants from the DOD in the development of its live Listeria vaccines directed against HER-2 for breast cancer and HMW-MAA, an antiangiogenic vaccine.

There are three (3) separate grant proposals that would:

a) fully fund a Phase 1 trial for ADXS31-164 in collaboration with a military medical research center;

b) fund additional manufacturing technology development, and additional pharmacology and toxicology research; and

c) work with the novel antigen HMW-MAA to further define it's use as an anti-angiogenic target that can be used to reduce the blood supply to tumors and thus starve their growth.

"Our Listeria platform is gaining much attention in the medical community," commented Advaxis CEO Thomas A. Moore. "We feel our technology is timely and that our shareholders will greatly benefit from such governmental funding instruments which may allow us to broaden our reach within the industry."

About Advaxis Vaccines

HER-2 Antigen:

The Company's HER-2/neu vaccine (ADXS31-164) targets internal and external sites on the HER-2 antigen associated with aggressive breast cancer. The leading Her-2 antibody product targets only one. Advaxis pre-clinical studies with this vaccine demonstrated its anti-tumor efficacy in a Her-2/neu transgenic animal model. In this study, control animals had a median survival of twenty-five (25) weeks with complete mortality observed at week thirty-three (33) whereas vaccine-treated animals had a median survival of forty-five (45) weeks with a 33% survival rate at fifty (50) weeks with 22% of them still tumor free. The Lm vaccine also inhibits the growth of HER2/neu positive metastatic tumors in brains and lungs of experimental animals [Seavey MM et al. Clin. Cancer Res. 2009; 15:924-32].

HMW-MAA Antigen:

The HMW-MAA research follows from development work that has resulted in patent applications for the use of two different antigens in a single live Listeria vaccine, such that HMW-MAA is used to attack tumor vascular growth while a different antigen is used to attack tumor growth directly. This antigen also has applicability as the target of a single antigen therapeutic vaccine.

About the U.S. Department of Defense Research

The office of the Congressionally Directed Medical Research Programs (CDMRP) manages Congressional Special Interest Medical Research Programs (CSI) encompassing breast, prostate, ovarian cancers, neurofibromatosis, military health and other specified areas. Since fiscal year 1992 the CDMRP has managed approximately $4.8 billion in Congressional appropriations for peer-reviewed research aimed to prevent, control and cure disease. Through fiscal year 2007 approximately 8,300 awards have been made to advance health care solutions via extramural grants, contracts and cooperative agreements

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

For further information on the Company, please visit: www.advaxis.com.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Contacts:
Advaxis, Inc.
Conrad Mir, 732-545-1590
Director, Business Development
Fax: 732-545-1084
conradmir@advaxis.com
www.advaxis.com

Defense News Published at National Homeland Security Knowledgebase Newswire: Security and Defence News RSS Feed
http://nationalhomelandsecurityknowledgebase.com/Feeds/main.xml

Submit your Defense news here: http://www.nationalhomelandsecurityknowledgebase.com/news_submit/submit_news.htm

More Defense Stocks info: Visit the Defense and Homeland Security Stocks Directory. Visit Here

Sign up for free newsletter, stock and sector news alerts at Investorideas.com
click here: http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.National Homeland Security Knowledgebase Newswire disclaims any content contained in these releases.